IL2

Zoledronic Acid in Combination With Interleukin-2 to Expand Vγ9Vδ2 T Cells After T-replete Haplo-identical Allotransplant

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

TREg Activation in the Treatment of the PELADE (Alopecia Areata)

FT819 in Subjects With B-cell Malignancies

Natural Killer-cell Therapy for Acute Myeloid Leukemia

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

HPV16 E6 TCR T Cells for Cervical Carcinoma

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

MIROCALS: Modifying Immune Response and OutComes in ALS

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma

Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors

Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC